Skip to content
  • About Us
    • Mission & Strategy
    • Our Story
    • Our Team
    • Careers
  • Inobrodib
    • Science
    • Clinical Trials
    • For Physicians
    • For Patients
  • News
    • Press Releases
    • Publications
  • Contact Us
  • About Us
    • Mission & Strategy
    • Our Story
    • Our Team
    • Careers
  • Inobrodib
    • Science
    • Clinical Trials
    • For Physicians
    • For Patients
  • News
    • Press Releases
    • Publications
  • Contact Us
Linkedin

Latest press releases

View all

CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting

7 December 2025 Press Release

CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

3 November 2025 Press Release

CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma 

9 September 2025 Press Release

Applications

Inobrodib is currently being evaluated for safety and efficacy in different multiple myeloma patient populations

FDC40D06-9F76-4E8A-AF33-68251D6B17C1

Multiple Myeloma

Multiple myeloma (MM) and other hematological malignancies are regulated in part by p300/CBP.

5ED9A5DB-1645-4854-AFCE-FF80DBBE114F
FDC40D06-9F76-4E8A-AF33-68251D6B17C1

Other Potential Applications

Inobrodib may have therapeutic utility in other p300/CBP-regulated cancers including acute myeloid leukemia (AML), lymphomas, solid tumors and targeted tumors with specific genetic mutations.

About CellCentric

CellCentric is a clinical-stage biopharmaceutical company focused on the development of a first-in-class oral p300/CBP inhibitor to treat multiple myeloma and other cancer types.

Quick Links

  • About Us
  • Inobrodib
  • Clinical Trials
  • Publications
  • Our Story
  • About Us
  • Inobrodib
  • Clinical Trials
  • Publications
  • Our Story
  • Our Team
  • News
  • Contact
  • Expanded Access Policy
  • Privacy Policy
  • Careers
  • Our Team
  • News
  • Contact
  • Expanded Access Policy
  • Privacy Policy
  • Careers

Follow us

Follow us and stay up to date with our latest news, events and scientific posters.

Icon-x Linkedin-in

© CellCentric Limited 2026 | Company #4948632

Main Menu
  • About Us
    • Mission & Strategy
    • Our Story
    • Our Team
    • Careers
  • Inobrodib
    • Science
    • Clinical Trials
    • For Physicians
    • For Patients
  • News
    • Press Releases
    • Publications
  • Contact Us
Follow us on LinkedIn